Tebotelimab

DB16685InvestigationalProtein Based Therapies

Tebotelimab is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).

Mechanism: Pharmacologically active on Programmed cell death protein 1 and Lymphocyte activation gene 3 protein
Curator reviewed
Also known as: MGD013 dual-affinity re-targeting (DART)
Code names: MGD-013 · MGD013 (PD-1 X LAG-3)

Resolves to

Compound

UNIIL62556GPXBCAS2245725-04-4

Targets

Q15116PDCD1P18627LAG3

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tebotelimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account